Company news
SELLAS Life Sciences Group, Inc. news in 2026
SELLAS Life Sciences Group, Inc.'s news releases, calls and decks from 2026, newest first.
SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
November 4, 2026
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
October 28, 2026
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer
September 25, 2026
SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer
September 2, 2026
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
March 18, 2026
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
March 16, 2026
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
March 11, 2026
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
January 14, 2026